Skip to content
DataLookout
Menu

NCT07851259

A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below.

  1. Minor Trial sites expanded: 5 → 9 locations
  2. Notable Recruitment opened
    • Start date pushed from Sep 30, 2026 to Jan 8, 2027
    • Trial sites expanded: 0 → 5 locations
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change of GA Lesion Area in the Study Eye
Timeframe: Baseline up to approximately 48 weeks
Incidence and Severity of Ocular Adverse Events (AEs)
Timeframe: Up to approximately 72 Weeks
Incidence and Severity of Non-Ocular AEs
Timeframe: Up to approximately 72 Weeks

Secondary (9)

Change of GA Lesion Area in the Study Eye
Change from Baseline in Best Correct Visual Acuity (BCVA) Score on the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart
Change from Baseline in BCVA Score on the ETDRS Chart Under Low-luminance Conditions
Incidence and Severity of Selected Findings in Ocular Examinations and Ocular Imaging
Plasma Concentration of RO7965032
Show 4 moreShow less
Percent Change from Baseline in Levels of Target Protein in Plasma
Percent Change from Baseline in Levels of Plasma Biomarker Activity
Prevalence and Incidence of Anti-Drug Antibodies (ADAs)
Recommended Dose of RO7965032

Arms and interventions

RO7965032 Dose Level 1Experimental

Participants will receive RO7965032.

RO7965032 Dose Level 2Experimental

Participants will receive RO7965032.

PlaceboPlacebo comparator

Participants will receive placebo.

Drugs: RO7965032, Placebo

Sites

9 sites in 1 country